Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2224 • 2012 ACR/ARHP Annual Meeting
Oral Contraceptive Pill Use in Women with Ankylosing Spondylitis Is Associated with a Younger Age At Diagnosis
Dharini Mahendira¹, Arane Thavaneswaran², Adele Carty³, Nigil Haroon⁴, Ammepa Anton⁵, Laura A. Passalent⁶, Khalid A. Alnaqbi³, Laurie M. Savage⁷, Elin Aslanyan⁷ and Robert D. Inman⁸, ¹Rheumatology, St Michael's Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine/Rheumatology, University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, Toronto, ON, Canada, ⁶Allied Health, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷Spondylitis Association of America, Van Nuys, CA, ⁸Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: While AS is traditionally recognized as a predominantly male disease, the impact of gender differences on AS pathogenesis has not been clearly established. Specifically,…
Abstract Number: 1381 • 2012 ACR/ARHP Annual Meeting
Non-Radiographic Spondyloarthritis Has Greater Work Instability Than Other Spondyloarthritis Subtypes in a National Database
Sherry Rohekar¹, Robert D. Inman², Renise Ayearst³, Proton Rahman⁴, Walter P. Maksymowych⁵ and Dafna D. Gladman⁶, ¹Rheumatology, St. Joseph's Hospital, London, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Clinical subsets of spondyloarthritis (SpA), such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA) can be associated with significant impact on work performance and…
Abstract Number: 591 • 2012 ACR/ARHP Annual Meeting
Structural Progression of Ankylosing Spondylitis Associated with Elevation in Two NOVEL, Inflammatory Biomarkers; Matrix Metalloproteinase and Cathepsin-Derived
Anne C. Bay-Jensen¹, Morten Asser Karsdal², Stephanie Wichuk³, Zheng Zhao⁴, Robert GW Lambert⁵, Per Qvist⁶ and Walter P. Maksymowych⁷, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience A/S, Herlev, Denmark, ³Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁵Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Nordic Bioscience, Herlev, Denmark, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Current inflammatory biomarkers, such as CRP, have insufficient sensitivity and specificity to be broadly accepted for diagnosis and prognosis of AS. We hypothesized, that…
Abstract Number: 493 • 2012 ACR/ARHP Annual Meeting
Effect of Infliximab On Employment Status in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis
W. Bensen¹, J. Carter Thorne², Saeed A. Shaikh³, Maqbool K. Sheriff⁴, Susan M. Otawa⁵, Allen J. Lehman⁵ and Hayssam Khalil⁶, ¹St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, McMaster University, St Catharines, ON, Canada, ⁴Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁶Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with significant functional impairment and work disability. In the absence of treatment, approximately 80% of…
Abstract Number: 2225 • 2012 ACR/ARHP Annual Meeting
Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)
Dominique L. Baeten¹, Stephan Bek², Jiawei Wei³, Arndt Brachat⁴, Joachim Sieper⁵, Paul Emery⁶, Jürgen Braun⁷, Desiree M. van der Heijde⁸, Iain B. McInnes⁹, Jacob M. van Laar¹⁰, R. Landewe¹¹, Paul Wordsworth¹², Jurgen Wollenhaupt¹³, Herbert Kellner¹⁴, Jacqueline E. Paramarta¹⁵, Arthur Bertolino¹⁶, Andrew Wright¹⁷ and Hueber Wolfgang², ¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Integrated Information Sciences (IIS), Beijing Novartis Pharma Co. Ltd., Shanghai,, China, ⁴Novartis Pharma AG, Novartis Pharma AG, Basel, Switzerland, ⁵Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁶Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany, ⁸Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹⁰Newcastle University, Musculoskeletal Research Group, Newcastle, United Kingdom, ¹¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹²Nuffield Orthopaedic Centre, Oxford, United Kingdom, ¹³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹⁴Centre for Inflammatory Joint Diseases, Munich, Germany, ¹⁵Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹⁶Translational Medicine- 3rd Floor, Novartis Institutes for BioMedical Research, Basel, Switzerland, ¹⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab has shown to be well tolerated and effective in active ankylosing spondylitis (AS) patients in a proof-of-concept trial1. Briefly, at Week (Wk) 6,…
Abstract Number: 1383 • 2012 ACR/ARHP Annual Meeting
The Burden of Ankylosing Spondylitis and the Cost-Effectiveness of Anti-Tumor Necrosis Factor α Agents in Romania
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Ankylosing Spondylitis (AS) usually affects young males, severely impairing their quality of life. Chronic treatment of AS using anti-TNF α agents is costly and…
Abstract Number: 592 • 2012 ACR/ARHP Annual Meeting
Two Novel Diagnostic Biomarkers of Cartilage Degradation and Connective Tissue Inflammation Are Predictive of Disease Progression in Ankylosing Spondylitis
Anne C. Bay-Jensen¹, Stephanie Wichuk², Inger Byrjalsen³, Zheng Zhao⁴, Robert GW Lambert⁵, Morten Asser Karsdal⁶ and Walter P. Maksymowych⁷, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Research & Development, Nordic Bioscience, Herlev, Denmark, ⁴Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁵Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Nordic Bioscience A/S, Herlev, Denmark, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Cartilage degradation and inflammation of synovial and connective tissue are key events in inflammatory arthropathies such as SpA. Presently there are no prognostic tools…
Abstract Number: 2652 • 2012 ACR/ARHP Annual Meeting
Benefits of Aerobic Training in Patients with Ankylosing Spondylitis Are Not Coupled by Effects On Cytokines: A Randomized Controlled Trial
Fabio Jennings¹, Hilda A. Oliveira², Marcelo C. Sousa¹, Vaneska G. Cruz¹, Fabio S. Lira³ and Jamil Natour¹, ¹Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Psicobiology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Ankylosing Spondylitis (AS) is a systemic inflammatory disease that causes deterioration of physical capacity. Although exercises remain essential in the treatment, the literature lacks…
Abstract Number: 2233 • 2012 ACR/ARHP Annual Meeting
Assessing the Clinical and Economic Burden of U.S. Veteran Ankylosing Spondylitis Patients
Lin Xie¹, Onur Baser², Ahong Huang³, Lu Li³, Elyse K. Fritschel³ and Li Wang⁴, ¹Director, Health Economics & Outcomes Research, STATinMED Research, Ann Arbor, MI, ²President/Adjunct Professor of Internal Medicine, STATinMED Research/The University of Michigan, Ann Arbor, MI, ³STATinMED Research, Dallas, TX, ⁴Director, Analytic Research, STATinMED Research, Dallas, TX
Background/Purpose: To examine the economic burden, demographic and clinical characteristics of ankylosing spondylitis (AS) in the U.S. veteran population. Methods: A retrospective database analysis…
Abstract Number: 1384 • 2012 ACR/ARHP Annual Meeting
The Frequency of Non-Radiographic Axial Spondyloarthritis in Relation to Symptom Duration in Patients Referred Because of Chronic Back Pain: Results From the Berlin Early Spondyloarthritis Clinic
Denis Poddubnyy¹, Henning Brandt², Janis Vahldiek³, Inge Spiller², In-Ho Song⁴, Martin Rudwaleit⁵ and Joachim Sieper⁶, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Medical Department I, Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, ³Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, ⁴Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ⁵Endokrinologikum Berlin, Berlin, Germany, ⁶Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axial SpA (=ankylosing spondylitis – AS) are considered currently as two stages of axial SpA. We reported recently…
Abstract Number: 597 • 2012 ACR/ARHP Annual Meeting
Investigating the Genetic Association Between ERAP1 and Spondyloarthritis
Amir Kadi¹, Brigitte Izac², Roula Said-Nahal³, Ariane Leboime⁴, Kurt L. de Vlam⁵, Dirk Elewaut⁶, Gilles Chiocchia² and Maxime A. Breban³, ¹Institut Cochin - Université Paris Descartes - INSERM U1016 - CNRS (UMR 8104), Paris, France, ²Immunology and Hematology Department, Institut Cochin - INSERM U1016 - CNRS (UMR 8104), Paris, France, ³Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁴Rheumatology Division, Ambroise-Paré Hospital AP-HP, Boulogne-Billancourt, France, ⁵Rheumatology, University Hospitals Leuven, Leuven, Belgium, ⁶Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium
Background/Purpose: A robust association was recently identified between polymorphisms in the non-major histocompatibility complex gene ERAP1 and ankylosing spondylitis (AS) in several populations. The aim…
Abstract Number: 2235 • 2012 ACR/ARHP Annual Meeting
How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters
Xenofon Baraliakos¹, Claudia Fritz², Joachim Listing³, Hildrun Haibel⁴, Joachim Sieper⁵ and Jürgen Braun⁶, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ⁵Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁶PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: Measures for disease activity (BASDAI) or response to therapy (ASAS partial remission (PR)) are widely used in the assessment of patients with ankylosing spondylitis…
Abstract Number: 1385 • 2012 ACR/ARHP Annual Meeting
Increased Body Mass Index in Ankylosing Spondylitis Is Associated with a Greater Burden of Symptoms and Poor Perceptions of the Benefits of Exercise
Laura J. Durcan¹, Fiona Wilson², Richard Conway¹, Gaye Cunnane³ and Finbar (Barry) D. O'Shea⁴, ¹Rheumatology, St James's Hospital, Dublin, Ireland, ²Physiotherapy, Trinity College, Dublin, Ireland, ³Dept of Rheumatology, St James's Hospital, Dublin, Ireland, ⁴Rheumatology Dept, St James's Hospital, Dublin, Ireland
Background/Purpose: In Ankylosing Spondylitis (AS) the effect of obesity on disease characteristics and exercise perceptions is unknown. Exercise is an essential component in the management…
Abstract Number: 598 • 2012 ACR/ARHP Annual Meeting
The Non-Synonymous Polymorphism IL23R Arg381Gln Is Associated with Ankylosis in Spondyloarthritis
Amir Kadi¹, Félicie Costantino², Brigitte Izac³, Ariane Leboime⁴, Roula Said-Nahal⁵, Gilles Chiocchia³ and Maxime A. Breban⁵, ¹Institut Cochin - Université Paris Descartes - INSERM U1016 - CNRS (UMR 8104), Paris, France, ²INSERM U987, Faculté des Sciences de la Santé Simone Veil, Montigny-le-Bretonneux, France, ³Immunology and Hematology Department, Institut Cochin - INSERM U1016 - CNRS (UMR 8104), Paris, France, ⁴Rheumatology Division, Ambroise-Paré Hospital AP-HP, Boulogne-Billancourt, France, ⁵Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France
Background/Purpose: Spondyloarthritis (SpA) is a group of articular disorders sharing genetic background. Single-nucleotide polymorphisms (SNP) of the interleukin 23 receptor (IL23R) gene have been reproducibly…
Abstract Number: 2213 • 2012 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Is Strongly Related to Clinical Spine Fractures Independently of Drugs Use: A Register-Based Case-Control Study
Daniel Prieto-Alhambra¹, Juan Muñoz-Ortego², Cyrus Cooper³, Adolfo Díez-Pérez⁴ and Peter Vestergaard⁵, ¹Internal Medicine; Primary Care; NDORMS Dept; MRC Lifecourse Epidemiology Unit, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, ²Rheumatology, Hospital Sagrat Cor, Barcelona (Spain), Spain, ³NDORMS; MRC Lifecourse Epidemiology Unit, University of Oxford; Southampton General Hospital, Southampton, United Kingdom, ⁴Internal Medicine, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, ⁵Endocrinology and Internal Medicine (MEA), Aarhus University Hospital THG, Aarhus (Denmark), Aarhus, Denmark
TITLE: "Ankylosing Spondylitis is strongly related to clinical spine fractures independently of drugs use: a register-based case-control study."Background/Purpose: Ankylosing Spondylitis (AS) is associated not only…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.